Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor

Experimental Neurology

Volumn 151, Issue 2, 1998, Pages 215-220

  Ohi, Takekazu ^a   Saita, Kazuko ^a   Furukawa, Shoei ^b   Ohta, Mitsuhiro ^b   Hayashi, Kyozo ^b   Matsukura, Shigeru ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b NONE

Author keywords

Aldose reductase inhibitor; CNTF; Diabetic neuropathy; NGF; Schwann cell culture

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; CILIARY NEUROTROPHIC FACTOR; EPALRESTAT; NERVE GROWTH FACTOR; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETIC NEUROPATHY; ELECTROPHYSIOLOGY; MALE; MOTOR NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHWANN CELL; SCIATIC NERVE; SENSORY NERVE CONDUCTION; STREPTOZOCIN DIABETES;

EID: 0032102882     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6821     Document Type: Article

References (38)

1. Apfel S. C., Arezzo J. C., Brownlee M., Federoff H., Kessler J. A. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 634:1994;7-12.
2. Apfel S. C., Wright D. E., Wiideman A. M., Dormia C., Snider W. D., Kessler J. A. Nerve growth factor regulates the expression of brain-derived neurotrophic factor mRNA in the peripheral nervous system. Mol. Cell. Neurosci. 7:1996;134-142.
3. Brown M. J., Summer A. J., Green D. A., Diamond S. M., Asbury A. K. Distal neuropathy in experimental diabetes mellitus. Ann. Neurol. 8:1980;168-178.
4. Brownlee M. Advanced products of nonenzymatic glycation and the pathogenesis of diabetic complications. Diabetes Mellitus. Theory and Practice. 1990;Elsevier, New York. p. 279-291.
5. Cameron N. E., Cotter M. A., Dines K. C., Hohman T. C. Reversal of defective peripheral nerve conduction velocity, nutritive endoneurial blood flow, and oxygenation by a novel aldose reductase inhibitor, WAY-121, 509, in streptozotocin-induced diabetic rats. J. Diab. Comp. 10:1996;43-53.
6. Cameron N. E., Cotter M. A., Dines K. C., Maxfield E. K., Carey F., Mirrlees D. J. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism. Diabetologia. 37:1994;651-663.
7. Dyck, P. J. 1989, Hypoxic neuropathy: Does hypoxia play a role in diabetic neuropathy?Neurology, 39, 111, 118.
8. Ernfors P., Lee K.-F., Kucera J., Juenisch R. Lack of neurotrophin-3 leads to deficiencies in the peripheral nervous system and loss of limb proprioception afferents. Cell. 77:1994;503-512.
9. Furukawa S., Kawano I., Furukawa Y., Akazawa S., Satoyoshi E., Itoh K., Hayashi K. A highly sensitive enzyme immunoassay for mouse beta nerve growth factor. J. Neurochem. 40:1983;737-744.
10. Gao W.-Q., Dybdai N., Shinsky N., Murnane A., Schmelzer C., Siegel M., Keller G., Hefti F., Phillips H. S., Winslow J. W. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann. Neurol. 38:1995;30-37.
11. Goto Y., Hotta N., Shigeta Y., Sakamoto N., Kito S., Matsuoka K., Takahashi A., Kikkawa R., Sakuma A. A placebo-controlled double-blind study of Epalrestat (ONO-2235) in patients with diabetic neuropathy. Diabet. Med. 1993.
12. Goda S., Hammer J., Kobiler D., Quarles R. H. Expression of myelin-associated glycoprotein in cultures of immortalized Schwann cells. J. Neurochem. 56:1991;1354-1361.
13. Green D. A., Lattimer S. A. Impaired rat sciatic nerve sodium-potassium adenosine triphosphate in acute streptozotocin diabetes and its correction by dietary myo-inositol supplementation. J. Clin. Invest. 72:1983;1058-1063.
14. Hanaoka Y., Ohi T., Furukawa S., Furukawa Y., Hayashi K., Matsukura S. Effect of 4-methylcatechol on sciatic nerve growth factor level and motor nerve conduction velocity in experimental diabetic neuropathic process in rats. Exp. Neurol. 115:1992;292-296.
15. Hanaoka Y., Ohi T., Furukawa S., Furukawa Y., Hayashi K., Matsukura S. The therapeutic effects of 4-methycatechol, a stimulator of endogenous nerve growth factor synthesis, on experimental diabetic neuropathy in rats. J. Neurol. Sci. 122:1994;28-32.
16. Hellweng R., Hartung H.-D. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus : A possible role for NGF in the pathogenesis of diabetic neuropathy. J. Neurosci. Res. 1990.
17. Hellweg R., Wöhrle M., Hartung H.-D., Stracke H., Hock C., Federlin K. Diabetes mellitus-associated decrease in nerve growth factor levels is reversed by allogeneic pancreatic islet transplantation. Neurosci. Lett. 125:1991;1-4.
18. Hotta N, Kakuta H., Fukasawa H., Kimura M., Koh N., Iida M., Terashima H., Morimura T., Sakamoto N. Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats. Diabetologia. 28:1985;176-180.
19. Jakobsen J., Brimijoin S., Skau K., Sidenius P., Wells D. Retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in streptozotocin-diabetic rats. Diabetes. 1981.
20. Kikkawa R., Hatanaka I., Yasuda H., Kobayashi N., Shigeta Y. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats. Metabolism. 33:1984;212-214.
21. Kikkawa R., Hatanaka I., Yasuda H., Kobayashi N., Shigeta Y., Terashima H., Morimura T., Tsuboshima M. Effects of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5((2E)-methyl-3-phenylpropenylidene) rhodanine (ONO-2235), on peripheral nerve disorders in streptozotocin-diabetic rats. Diabetologia. 24:1983;290-292.
22. Ohi T., Furukawa S., Hayashi K., Matsukura S. Ganglioside stimulation of nerve growth factor synthesis in cultured rat Schwann cells. Biochem. Int. 20:1990;739-746.
23. Ohta M., Ohi T., Nishimura M., Itoh N., Hayashi K., Ohta K. Distribution of age-related changes in ciliary neurotrophic factor protein in rat tissues. Biochem. Mol. Biol. Int. 40:1996;671-678.
24. Sasagasako N., Toda K., Hollis M., Quarles R. H. Myelin gene expression in immortalized Schwann cells : Relationship to cell density and proliteration. J. Neurochem. 66:1996;1432-1439.
25. 125. Diabetes. 32:1983;654-663.
26. Sharma A. K., Thomas P. K. Animal models: Pathology and pathophysiology. Dyck P. J., Thomas P. K., Asbury A. K., Winegrad A. I., Porter D. Jr. Diabetic Neuropathy. 1987;237-252 Saunders, Philadelphia.
27. Sima A. A. F., Green D. A., Brown M. B., Hohman T. C., Hicks D., Graepol G. J., Bochnek W. J., Beg M., Gonen B. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. J. Diab. Comp. 7:1993;157-169.
28. Stanley E. F. Sensory and motor nerve conduction velocities and the latency of the H reflex during growth of the rat. Exp. Neurol. 71:1981;497-506.
29. Tsai S. C., Burnakis T. G. Aldose reductase inhibitors: An update. Ann. Pharmacother. 1993.
30. Tuck R. R., Schmelzer J. D., Low P. A. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain. 1984.
31. Uchida K., Kigoshi T., Nakano S., Ishii T., Kitazawa M., Morimoto S. Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. Clin. Ther. 17:1995;460-466.
32. Vink A. I., Liuzzi F. J., Holland M. T., Stansberry K. B., Lebeau J. M., Colen L. B. Diabetic neuropathies. Diabetes Care. 15:1995;1926-1975.
33. 2. Prostagland. 44:1991;233-236.
34. Ward J. D. Biochemical and vascular factors in the pathogenesis of diabetic neuropathy. Clin. Invest. Med. 18:1995;267-274.
35. Ward K. K., Low P. A., Schmelzer J. D., Zochodne D. W. Prostacyclin and noradrenaline in peripheral nerve of chronic experimental diabetes in rats. Brain. 1989.
36. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab. Rev. 11:1995;193-225.
37. Yamaguchi K., Tsuji T., Uemura D., Kondo K. Cyclooxygenase induction is essential for NGF synthesis enhancement by NGF inducers in L-M cells. Biosci. Biotech. Biochem. 60:1996;92-94.
38. Yuen E. C., Mobley W. C. Therapeutic potential of neurotrophic factors for neurological disorders. Ann. Neurol. 1996.